Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FBXW7 E192A |
Therapy | Sirolimus |
Indication/Tumor Type | fibrolamellar carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FBXW7 E192A | fibrolamellar carcinoma | predicted - sensitive | Sirolimus | Case Reports/Case Series | Actionable | In a Phase I study, Rapamune (sirolimus) resulted in prolonged stable disease in a patient with hepatocellular fibrolamellar carcinoma harboring FBXW7 E192A (PMID: 24586741). | 24586741 |
PubMed Id | Reference Title | Details |
---|---|---|
(24586741) | FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. | Full reference... |